Ziopharm oncology inc (ZIOP)
Income statement / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Sep'10Jun'10Sep'09
Collaboration revenue

-

-

-

-

-

146

1,743

3,341

4,938

6,389

6,389

6,389

6,489

6,861

7,183

7,454

6,029

4,332

2,753

1,517

1,445

1,373

1,233

800

800

800

800

800

800

800

800

800

800

667

0

0

0

-

-

0

Operating expenses:
Research and development

41,561

38,331

36,314

35,936

33,427

34,134

37,116

39,958

43,300

45,084

43,292

41,162

159,559

157,791

156,544

164,539

42,735

106,785

106,728

99,491

100,413

32,706

27,339

23,853

30,282

42,852

75,116

85,084

88,573

83,446

61,114

55,566

46,427

57,083

50,144

41,699

0

0

0

0

General and administrative

21,336

19,527

18,270

17,770

17,904

19,918

19,207

18,471

17,362

14,798

14,265

14,231

14,162

14,377

14,317

13,845

17,207

17,647

17,239

17,016

12,974

12,166

13,516

13,742

14,432

15,661

15,521

18,165

19,346

19,523

19,429

17,459

16,480

14,984

13,806

12,958

0

0

0

0

Total operating expenses

62,897

57,858

54,584

53,706

51,331

54,052

56,323

58,429

60,662

59,882

57,557

55,393

173,721

172,168

170,861

178,384

59,942

124,432

123,967

116,507

113,387

44,872

40,855

37,595

44,714

58,513

90,637

103,249

107,919

102,969

80,543

73,025

62,907

72,067

63,950

54,657

0

0

0

0

Loss from operations

-62,897

-57,858

-54,584

-53,706

-51,331

-53,906

-54,580

-55,088

-55,724

-53,493

-51,168

-49,004

-167,232

-165,307

-163,678

-170,930

-53,913

-120,100

-121,214

-114,990

-111,942

-43,499

-39,622

-36,795

-43,914

-57,713

-89,837

-102,449

-107,119

-102,169

-79,743

-72,225

-62,107

-71,400

-63,483

-54,390

0

0

0

0

Other income, net

993

813

692

639

670

631

628

653

575

465

331

195

151

134

108

65

37

12

7

13

0

-5

-397

-590

-584

-579

-136

13

9

-13

-52

9

15

39

33

27

0

0

0

0

Non-cash inducement warrant expense

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Change in fair value of warrants

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

11,723

9,736

-3,518

-9,521

1,185

11,544

22,896

22,649

6,050

644

10,087

12,852

7,583

711

1,465

0

0

0

0

Change in fair value of derivative liabilities

-

-

-

-

-

158

43

410

293

-1,295

-1,271

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net loss

-122,655

-117,796

92,488

153,899

156,488

153,902

-53,909

-54,025

-54,856

-54,323

-52,274

-50,427

-168,765

-165,297

-163,549

-170,865

-53,876

-120,088

-121,013

-108,936

-100,301

-31,781

-30,283

-40,903

-54,019

-57,107

-78,429

-79,540

-84,461

-96,132

-79,151

-62,129

-49,240

-63,778

-62,739

-52,898

0

0

0

0

Preferred stock dividends

-

-

-

-

-

16,998

21,655

20,484

19,887

18,938

17,530

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net income (loss) applicable to common stockholders

-

-

92,488

147,825

-

137,246

-75,564

-74,509

-74,743

-73,261

-69,745

-66,586

-180,059

-172,420

-175,834

0

0

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Basic and diluted net loss per share

-0.09

-

-0.43

-0.09

-0.08

-

-0.13

-0.12

-0.15

-

-0.13

-0.13

-0.15

-

-0.11

-1.01

-0.09

-0.02

-0.14

-0.11

-0.69

-0.09

-0.06

-0.06

-0.10

-0.09

-0.20

-0.22

-0.15

-0.37

-0.23

-0.30

-0.32

-

-

-

-0.65

-

-

-

Net income (loss) per share - basic

-

-

-

-

-

1.29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.01

-0.16

-

-0.26

0.21

-0.13

Net income (loss) per share - diluted

-

-

-

-

-

1.29

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-0.01

-0.16

-

-0.26

0.19

-0.13

Weighted average common shares outstanding used to compute basic and diluted net loss per share

199,814

-

170,613

160,789

160,640

-

141,185

141,017

140,853

-

140,632

135,630

130,696

-

130,496

130,385

130,157

130,108

129,732

128,413

113,410

103,442

100,428

100,422

100,229

94,622

83,161

83,082

82,906

81,379

78,670

78,514

75,620

-

-

-

60,412

-

-

-

Weighted average common shares outstanding used to compute basic net income (loss) per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

68,104

67,229

-

47,426

42,364

21,759

Weighted average common shares outstanding used to compute diluted net income (loss) per share

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

68,104

67,229

-

47,426

48,822

21,759